Last reviewed · How we verify
Beta-lactamase inhibitor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Beta-lactamase inhibitor (Beta-lactamase inhibitor) — Guangzhou Institute of Respiratory Disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Beta-lactamase inhibitor TARGET | Beta-lactamase inhibitor | Guangzhou Institute of Respiratory Disease | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Beta-lactamase inhibitor CI watch — RSS
- Beta-lactamase inhibitor CI watch — Atom
- Beta-lactamase inhibitor CI watch — JSON
- Beta-lactamase inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). Beta-lactamase inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/beta-lactamase-inhibitor. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab